MedTrace Logo

Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)

NCT00894686 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2018-12-17

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the first booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5 mL in precursor Study 700401.

Conditions

  • Encephalitis, Tick-Borne

Interventions

BIOLOGICAL

FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)

Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

  • Eva-Maria Pöllabauer, MD · Baxter Healthcare Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-26
Primary Completion
2017-05-10
Completion
2017-05-10

Countries

  • Austria
  • Germany
  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00894686 on ClinicalTrials.gov